Patents by Inventor Beatrice Cameron

Beatrice Cameron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160368977
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 22, 2016
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 9493529
    Abstract: The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant protein. Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: November 15, 2016
    Assignee: Sanofi
    Inventors: Francis Blanche, Beatrice Cameron, Tarik Dabdoubi, Frederique Dol-Gleizes, Pierre Fons, Catherine Prades, Jean-Pascal Herault
  • Publication number: 20160280793
    Abstract: Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy.
    Type: Application
    Filed: June 26, 2015
    Publication date: September 29, 2016
    Inventors: Yves BAUDAT, Francis BLANCHE, Béatrice CAMERON, Tarik DABDOUBI, Anne-Marie LEFEBVRE, Magali MATHIEU, Ana MERINO-TRIGO, Manoel NUNES
  • Patent number: 9441040
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 13, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Patent number: 9382312
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 5, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20160176970
    Abstract: The present invention relates to a peptide or peptide complex binding to ?2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting ?2 integrin and a screening method.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 23, 2016
    Inventors: Carsten Corvey, Horst Blum, Béatrice Cameron, Tarik Dabdoubi, Stephanie Decary, Nicolas Baurin, David Papin, Christian Lange
  • Publication number: 20160108131
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: May 19, 2015
    Publication date: April 21, 2016
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Patent number: 9243067
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 26, 2016
    Assignee: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Patent number: 9234039
    Abstract: The present invention relates to a peptide or peptide complex binding to ?2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting ?2 integrin and a screening method.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: January 12, 2016
    Assignee: SANOFI
    Inventors: Carsten Corvey, Horst Blum, Béatrice Cameron, Tarik Dabdoubi, Stephanie Decary, Nicolas Baurin, David Papin, Christian Lange
  • Patent number: 9228019
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 5, 2016
    Assignee: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Patent number: 9175087
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: November 3, 2015
    Assignee: Sanofi
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Publication number: 20150098939
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 9, 2015
    Applicant: SANOFI
    Inventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Carsten CORVEY, Tarik DABDOUBI, Christian ENGEL, Peter FLORIAN, Ingo FOCKEN, Katja KROLL, Jochen KRUIP, Christian LANGE, Thomas LANGER, Martin LORENZ, Vincent MIKOL, Ercole Rao, Peter WONEROW
  • Patent number: 8980262
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 17, 2015
    Assignee: Sanofi
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Patent number: 8852593
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: October 7, 2014
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Publication number: 20140105890
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 17, 2014
    Applicant: SANOFI
    Inventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Marc DUCHESNE, Vincent MIKOL, Souad NAIMI, Laurent PRADIER, Yi SHI
  • Publication number: 20140046032
    Abstract: The present invention relates to a method for producing an IgG antibody, wherein at least 80% of the said antibody comprises a complex, bi-antennary oligosaccharide, which contains two sialic acid residues, attached to the Fc domain of the antibody. The said method comprises the steps of introducing a mutation in the Fc domain of the antibody, and expressing the mutant antibody in a cell which expresses a galactosyltransferase and a sialyltransferase activity.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 13, 2014
    Applicant: SANOFI
    Inventors: Francis Blanche, Beatrice Cameron, Bruno Genet, Fabienne Soubrier
  • Patent number: 8647622
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: February 11, 2014
    Assignee: Sanofi
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicolas Baurin
  • Publication number: 20140030265
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 30, 2014
    Applicant: AVENTIS PHARMA SA
    Inventors: Francis BLANCHE, Béatrice CAMERON, Sylvie SORDELLO, Céline NICOLAZZI, Marc TROMBE, Mark NESBIT
  • Patent number: 8614299
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 24, 2013
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20130251714
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 26, 2013
    Applicant: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin